MGI(SH:688114) Cai Jing Wang·2025-10-24 05:46Core Insights - Shenzhen BGI Genomics Co., Ltd. reported a slight decline in revenue for the first three quarters of 2025, with total revenue at 1.87 billion yuan, a year-on-year decrease of 0.01% [1] - The company reduced its net loss from 463 million yuan in the same period last year to 120 million yuan, indicating an improvement in financial performance [1] - Research and development expenses amounted to 123 million yuan, representing 16.27% of total revenue, which is a decrease compared to the same period last year [1] Financial Performance - For Q3 2025, the company achieved revenue of 755 million yuan, a year-on-year increase of 14.5% [1] - The net loss for Q3 decreased from 165 million yuan to 16 million yuan, showing a significant reduction in losses [1] - The adjusted net loss also improved from 173 million yuan to 25.39 million yuan in Q3 [1] Operational Strategy - The company emphasized its strategy of cost reduction and efficiency improvement, focusing on core projects to optimize resource allocation [1]